Business Context and Reporting Period
This Form 8-K filing by Accuray Incorporated (Accuray) was submitted on May 11, 2012. The report discloses a corporate governance event: the appointment of a new independent director to the Board of Directors.
Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
The material change reported is the appointment of Richard R. Pettingill as a Class 1 member of the Accuray Board of Directors on May 11, 2012. Mr. Pettingill is an independent director with prior executive experience at Allina Hospitals and Clinics and Kaiser Foundation Health Plans. He is expected to stand for re-election at the 2013 annual meeting of stockholders.
Compensation and Governance Details
Mr. Pettingill's compensation package aligns with that of other non-employee Board members and includes the following:
- Cash Retainer: $35,000 annually for Board service (up to four meetings).
- Committee Fees: Additional annual fees of $10,000 for the Audit Committee, $5,000 for the Compensation Committee, and $3,000 for the Nominating and Corporate Governance Committee.
- Excess Meeting Fees: $1,000 per in-person meeting and $500 per telephonic meeting beyond the standard allotment.
- Initial Equity Grant: A stock option grant valued at $70,000 (based on fair market value on the grant date), vesting fully on the first anniversary of appointment.
- Annual Equity Grant: Restricted Stock Units (RSUs) valued at $120,000 annually, vesting one year after the annual meeting.
- Change in Control: Vesting of all option and RSU grants accelerates in full upon a change in control of Accuray.
No related party transactions or special arrangements were disclosed.
Key Facts for Investor Verification
- Confirm the exact grant date and fair market value per share used to calculate the initial $70,000 stock option grant.
- Verify the specific standing committees, if any, to which Mr. Pettingill is appointed to determine applicable committee fees.
- Review the attached press release (Exhibit 99.1) for additional context on the strategic rationale for this appointment.
- Note that this filing contains no financial results; investors should refer to the most recent 10-Q or 10-K for financial performance data.